Poseida Therapeutics (STU:2RZ) Short-Term Capital Lease Obligation : €5.61 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Short-Term Capital Lease Obligation?

Poseida Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was €5.61 Mil.

Poseida Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (€5.46 Mil) to Mar. 2024 (€5.52 Mil) and increased from Mar. 2024 (€5.52 Mil) to Jun. 2024 (€5.61 Mil).

Poseida Therapeutics's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€5.61 Mil) to Dec. 2022 (€5.54 Mil) and declined from Dec. 2022 (€5.54 Mil) to Dec. 2023 (€5.46 Mil).

Poseida Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Poseida Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Short-Term Capital Lease Obligation Chart

Poseida Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.95

5.61

5.54

5.46

Poseida Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.41	5.53	5.46	5.52	5.61

Poseida Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Poseida Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PSTX:USA

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics Headlines

No Headlines